Cathay Biotech Inc.
Shanghai Stock ExchangeTotal Valuation
Cathay Biotech Inc. carries a market capitalization of 35.67B, placing it among publicly traded companies globally. Its enterprise value stands at 22.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 35.67B |
| Enterprise Value | 22.40B |
Share Statistics
Cathay Biotech Inc. currently has 721.29M shares outstanding.
| Shares Outstanding | 721.29M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Cathay Biotech Inc. trades at a trailing price-to-earnings ratio of 50.97. The price-to-sales ratio is 8.81, and the price-to-book ratio stands at 9.20.
| PE Ratio | 50.97 |
| PS Ratio | 8.81 |
| PB Ratio | 9.20 |
| P/TBV Ratio | 1.38 |
| P/FCF Ratio | 44.04 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Cathay Biotech Inc. trades at an EV/EBITDA multiple of 39.31 and an EV/FCF ratio of 34.27. The EV/Sales ratio of 7.03 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 39.31 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.03 |
| EV / EBITDA | 39.31 |
| EV / EBIT | 39.31 |
| EV / FCF | 34.27 |
Financial Position
Cathay Biotech Inc. maintains a current ratio of 6.40, meaning it holds 6.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.63, indicating elevated leverage, while an interest coverage ratio of 28.63 demonstrates strong ability to service its debt obligations.
| Current Ratio | 6.40 |
| Quick Ratio | 5.24 |
| Debt / Equity | 2.63 |
| Debt / EBITDA | 0.97 |
| Interest Coverage | 28.63 |
Financial Efficiency
Cathay Biotech Inc. posts a return on equity of 18.85 and a return on invested capital of 2.54.
| Return on Equity (ROE) | 18.85 |
| Return on Assets (ROA) | 2.61 |
| Return on Invested Capital (ROIC) | 2.54 |
| Return on Capital Employed (ROCE) | 8.07 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.72 |
Taxes
Over the trailing twelve months, Cathay Biotech Inc. has paid 94.59M in income taxes, reflecting an effective tax rate of 15.52.
| Income Tax | 94.59M |
| Effective Tax Rate | 15.52 |
Stock Price Statistics
Cathay Biotech Inc.'s stock has gained approximately 7.45166% over the past 52 weeks. The 50-day moving average sits at 45.81, while the 200-day moving average is 49.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | 7.45166% |
| 50-Day Moving Average | 45.81 |
| 200-Day Moving Average | 49.89 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cathay Biotech Inc. generated 3.18B in revenue and converted that into 550.18M in net income, yielding earnings per share of 0.86. EBITDA reached 569.78M, while operating income came in at 569.78M.
| Revenue | 3.18B |
| Gross Profit | 1.04B |
| Operating Income | 569.78M |
| Pretax Income | 609.26M |
| Net Income | 550.18M |
| EBITDA | 569.78M |
| EBIT | 569.78M |
| Earnings Per Share (EPS) | 0.86 |
Balance Sheet
Cathay Biotech Inc. holds 9.82B in cash and equivalents against 554.98M in total debt, resulting in a net debt position of -8.18B. Total book value stands at 3.05B, with working capital of 10.14B providing operational flexibility.
| Cash & Cash Equivalents | 9.82B |
| Total Debt | 554.98M |
| Net Debt | -8.18B |
| Equity (Book Value) | 3.05B |
| Book Value Per Share | 5.12 |
| Working Capital | 10.14B |
Cash Flow
After subtracting -636.88M in capital expenditures, free cash flow totaled -636.88M - equivalent to -1.07 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -636.88M |
| Free Cash Flow | -636.88M |
| FCF Per Share | -1.07 |
Margins
Cathay Biotech Inc. operates with a gross margin of 32.62, reflecting its pricing power and cost economics. The operating margin of 17.89 and net profit margin of 17.28 provide insight into operational efficiency.
| Gross Margin | 32.62 |
| Operating Margin | 17.89 |
| Pretax Margin | 19.13 |
| Profit Margin | 17.28 |
| EBITDA Margin | 17.89 |
Dividends & Yields
The company's payout ratio of 29.25 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.24 |
| Dividend Yield | N/A |
| Payout Ratio | 29.25 |
| Shareholder Yield | -18.11 |
| FCF Yield | 2.27 |
Stock Splits
Cathay Biotech Inc.'s most recent stock split took place on July 20, 2022 with a 5:7 split ratio.
| Last Split Date | 7/20/2022 |
| Split Ratio | 5:7 |
Scores
Cathay Biotech Inc. posts an Altman Z-Score of 7.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.01 |